Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 1.75 USD -0.79% Market Closed
Market Cap: 82.4m USD

Relative Value

The Relative Value of one ADAG stock under the Base Case scenario is 1.05 USD. Compared to the current market price of 1.75 USD, Adagene Inc is Overvalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ADAG Relative Value
Base Case
1.05 USD
Overvaluation 40%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
18
vs Industry
15
Median 3Y
9.6
Median 5Y
6.4
Industry
7.9
Forward
11.4
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-3.2
Industry
23.7
Forward
-3.2
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-3.3
Industry
22
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-3.5
Industry
23.8
vs History
36
vs Industry
52
Median 3Y
1.8
Median 5Y
1.8
Industry
3.3
vs History
9
vs Industry
77
Median 3Y
3.4
Median 5Y
-2.6
Industry
8.3
Forward
3.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
27
Median 3Y
-0.4
Median 5Y
0.6
Industry
6.4
Forward
-0.7
vs History
vs Industry
24
Median 3Y
-0.4
Median 5Y
-0.8
Industry
7
Forward
-0.7
vs History
vs Industry
23
Median 3Y
-0.5
Median 5Y
-0.7
Industry
8.3
vs History
vs Industry
19
Median 3Y
-0.5
Median 5Y
-0.7
Industry
6.5
vs History
9
vs Industry
27
Median 3Y
-0.4
Median 5Y
8.4
Industry
5.7

Multiples Across Competitors

ADAG Competitors Multiples
Adagene Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Adagene Inc
NASDAQ:ADAG
83.1m USD 798.9 -2.8 -0.7 -0.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 790 068.7 -160 599.2 -195 018.6 -192 793.2
US
Abbvie Inc
NYSE:ABBV
394.7B USD 6.6 168.1 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
170.9B USD 4.8 24.4 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
149.5B USD 5.1 18.4 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.9 -532 -579.3 -563.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD 5.5 17 16.2 18.3
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.7 13.2 16.5
NL
argenx SE
XBRU:ARGX
46.1B EUR 15 35.3 61 62.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.4B USD 16 1 180.4 154.9 187.9
P/S Multiple
Revenue Growth P/S to Growth
CN
Adagene Inc
NASDAQ:ADAG
Average P/S: 3 072 092.6
798.9
306%
2.6
FR
Pharnext SCA
OTC:PNEXF
33 790 068.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 084.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16
46%
0.3
P/E Multiple
Earnings Growth PEG
CN
Adagene Inc
NASDAQ:ADAG
Average P/E: 186.8
Negative Multiple: -2.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 599.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.1
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
9%
1.9
AU
CSL Ltd
ASX:CSL
19.7
11%
1.8
NL
argenx SE
XBRU:ARGX
35.3
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 180.4
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Adagene Inc
NASDAQ:ADAG
Average EV/EBITDA: 39.3
Negative Multiple: -0.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 018.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
13.2
8%
1.7
NL
argenx SE
XBRU:ARGX
61
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
154.9
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Adagene Inc
NASDAQ:ADAG
Average EV/EBIT: 45.3
Negative Multiple: -0.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 793.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
62.7
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
187.9
N/A N/A